全文获取类型
收费全文 | 121篇 |
免费 | 8篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 13篇 |
基础医学 | 20篇 |
口腔科学 | 1篇 |
临床医学 | 3篇 |
内科学 | 8篇 |
皮肤病学 | 2篇 |
神经病学 | 55篇 |
外科学 | 10篇 |
预防医学 | 3篇 |
药学 | 5篇 |
肿瘤学 | 6篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 1篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 4篇 |
2013年 | 8篇 |
2012年 | 12篇 |
2011年 | 12篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 7篇 |
2007年 | 4篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 1篇 |
2000年 | 5篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 3篇 |
排序方式: 共有129条查询结果,搜索用时 15 毫秒
1.
ABSTRACTIntroduction: The safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors has continued to evolve with the availability of data from clinical trial programs, post-marketing pharmacovigilance and dedicated cardiovascular outcome trials.Areas covered: This article reviews the safety issues associated with the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin, particularly the newer/emergent safety data related to US Food and Drug Administration statements regarding these three agents.Expert opinion: The safety profile of SGLT2 inhibitors is well defined, and the adverse event profile is largely consistent with their mechanism of action. These well-recognized events include genital mycotic infections and volume-associated adverse events. Serious safety issues detected more recently with SGLT2 inhibitor therapy, such as bone fractures, pyelonephritis, urosepsis, and ketoacidosis, have been uncommon. A robust improvement in cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) was recently demonstrated with empagliflozin. Given the glucose-lowering efficacy, low risk of hypoglycemia, and other benefits associated with SGLT2 inhibitor therapy, this class of oral glucose-lowering medication is a valuable addition to treatment options for T2DM, and may play an increasingly prominent therapeutic role as emerging data are revealed. 相似文献
2.
3.
4.
5.
6.
Díaz TM Mañez R Moscoso I López D Santamarina I Lopez E Centeno A Domenéch N 《Transplantation proceedings》2005,37(1):510-511
The ability of human complement regulatory molecules to prevent xenograft rejection following pig-to-primate xenotransplantation is limited. We assayed the efficacy of transgenic human decay accelerating factor (hDAF) expressed on porcine cells to inhibit the in vitro complement activity of primate sera. We measured the cytotoxic activity of baboon or human sera against peripheral blood lymphocytes (PBLs) from hDAF or nontransgenic pigs using a flow cytometry complement-mediated cytotoxicity assay (FCCA). We also analyzed the anti-Galalpha1-3Gal (alphaGal) antibody titer of the baboon sera by ELISA and the expression of hDAF and alphaGal on the PBL surface by immunofluorescence. Transgenic hDAF expression was capable of protecting pig cells against injury produced by both baboon and human serum. However, the hDAF molecule was more efficient against human than baboon sera. The humoral cytotoxicity capacity correlated with the level of both IgG and IgM anti-alphaGal antibodies. In addition, inhibition of complement-mediated cytotoxicity of hDAF pig cells correlated with the expression of hDAF and alphaGal molecules on target cells. These results confirm in vitro the protective role of hDAF in pig cells to heterologus complement mediated damage, but they also suggest that protection decreases in the presence of high levels of anti-porcine antibodies in serum, low expression of hDAF, or high expression of alphaGal on pig cells. 相似文献
7.
8.
9.
Santamarina RD Besocke AG Romano LM Ioli PL Gonorazky SE 《Clinical neuropharmacology》2008,31(2):80-85
Anabolic-androgenic steroid (AAS) abuse increased in recent years, and it is associated with numerous adverse effects. Few reports on ischemic stroke related to anabolic steroid abuse have been published. We report a case of a 26-year-old male amateur athlete who suffered a posterior territory ischemic stroke. No abnormalities were found in angiography and echocardiography studies, neither in hemostatic profile. His only significant risk factor was nonmedical use of stanozolol, an anabolic steroid. Anabolic steroids are capable of increasing vascular tone, arterial tension, and platelet aggregation; therefore, they are prone to produce atherothrombotic phenomena. Because of young people's widespread use of anabolic steroids, physicians should be aware of this kind of complication. 相似文献
10.